Boehringer Ingelheim Debuts Short Film in Dubai to Drive Early Awareness of Pulmonary Fibrosis

Boehringer Ingelheim has premiered a new short film in Dubai as part of a targeted campaign to raise awareness regarding idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, two debilitating lung conditions that severely impact daily life. The premiere gathered leading pulmonology and rheumatology experts, including Dr Bassam Mahboub, vice president of the Emirates Thoracic Society, and Dr Shamma Al Nokhatha, president of the Emirates Society for Rheumatology, to emphasize the critical need for earlier symptom recognition.

Both IPF and PPF involve progressive lung scarring, leading to irreversible declines in lung function and oxygen intake. While the exact cause remains unknown in IPF, PPF can develop alongside other conditions such as rheumatoid arthritis. Common warning signs like a persistent dry cough, fatigue, and shortness of breath are frequently misattributed to normal aging or lack of fitness, often delaying vital diagnoses by one to two years despite the conditions affecting millions globally.

“We have been working in respiratory health for generations, and we know that scientific progress must go hand in hand with greater disease awareness and timely diagnosis,” stated Ousama Alhaj, general manager and head of human pharma at Boehringer Ingelheim, Near East and UAE. Highlighting recent approvals of new treatment options after a decade of stagnation, medical leaders stress that translating pharmaceutical advancements into earlier patient interventions remains the ultimate goal for improving outcomes in respiratory care.